ID

17460

Description

Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation; ODM derived from: https://clinicaltrials.gov/show/NCT00357591

Lien

https://clinicaltrials.gov/show/NCT00357591

Mots-clés

Versions (2)
  1. 15/09/2016 15/09/2016 -
  2. 16/09/2016 16/09/2016 -
Téléchargé le

16 septembre 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Heart Failure, Congestive NCT00357591

Anglais

Eligibility Heart Failure, Congestive NCT00357591

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. patients hospitalized due to decompensated heart failure who require iv inotropic and/or vasodilator and diuretic therapy
Description

Hospitalization Due to Decompensated cardiac failure | Inotropic agent Intravenous Patient need for | Vasodilator Agents Patient need for | Diuretic therapy Patient need for

Type de données

boolean

Alias
UMLS CUI [1,1]
C0019993
UMLS CUI [1,2]
C0678226
UMLS CUI [1,3]
C0581377
UMLS CUI [2,1]
C0304509
UMLS CUI [2,2]
C1522726
UMLS CUI [2,3]
C0686904
UMLS CUI [3,1]
C0042402
UMLS CUI [3,2]
C0686904
UMLS CUI [4,1]
C0948575
UMLS CUI [4,2]
C0686904
2. patients receiving appropriate medical therapy for heart failure, defined as ace inhibitors and beta blockers (all unless not tolerated or contraindicated) and diuretics, for 1 month prior to study entry
Description

Therapeutic procedure Appropriate Heart failure | Angiotensin-Converting Enzyme Inhibitors | Adrenergic beta-Antagonists | intolerance to Angiotensin-Converting Enzyme Inhibitors | intolerance to Adrenergic beta-Antagonists | Medical contraindication Angiotensin-Converting Enzyme Inhibitors | Medical contraindication Adrenergic beta-Antagonists | Diuretics

Type de données

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1548787
UMLS CUI [1,3]
C0018801
UMLS CUI [2]
C0003015
UMLS CUI [3]
C0001645
UMLS CUI [4,1]
C1744706
UMLS CUI [4,2]
C0003015
UMLS CUI [5,1]
C1744706
UMLS CUI [5,2]
C0001645
UMLS CUI [6,1]
C1301624
UMLS CUI [6,2]
C0003015
UMLS CUI [7,1]
C1301624
UMLS CUI [7,2]
C0001645
UMLS CUI [8]
C0012798
3. for at least 24 hours prior to inclusion into the study, the patient should be treated with a minimum dose of the following: dobutamine 2.5μg/kg/min or milrinone 0.3μg/kg/min or dopamine 5μg/kg/min. or nesiritide 0.01μg/kg/min or nitroglycerin 0.3
Description

Dobutamine Dosage Minimum | Milrinone Dosage Minimum | Dopamine Dosage Minimum | Nesiritide Dosage Minimum | Nitroglycerin Dosage Minimum

Type de données

boolean

Alias
UMLS CUI [1,1]
C0012963
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C1524031
UMLS CUI [2,1]
C0128513
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C1524031
UMLS CUI [3,1]
C0013030
UMLS CUI [3,2]
C0178602
UMLS CUI [3,3]
C1524031
UMLS CUI [4,1]
C0054015
UMLS CUI [4,2]
C0178602
UMLS CUI [4,3]
C1524031
UMLS CUI [5,1]
C0017887
UMLS CUI [5,2]
C0178602
UMLS CUI [5,3]
C1524031
µg/kg/min or nitroprusside 0.3 µg/kg/min or a combination of any of these agents, with diuretic therapy. doses of the above stated medications should be stable for 6 hours prior to inclusion into study. an increase in this dosage within the first 8 hours after enrollment is determined by the attending physician to be unlikely and the following definition of "not responding adequately to iv inotropic and/or vasodilator and diuretic therapy" is exhibited:
Description

Nitroprusside Dosage Minimum | Combined Modality Therapy | Diuretic therapy | Pharmaceutical Preparations Dosage Stable

Type de données

boolean

Alias
UMLS CUI [1,1]
C0028193
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C1524031
UMLS CUI [2]
C0009429
UMLS CUI [3]
C0948575
UMLS CUI [4,1]
C0013227
UMLS CUI [4,2]
C0178602
UMLS CUI [4,3]
C0205360
pcwp is ≥ 20 mmhg at time of randomization and pcwp was ≥ 18 mmhg continuously for 24 hours or pcwp ≥ 20 mmhg continuously for 12 hours prior to randomization.
Description

Pulmonary Capillary Wedge Pressure

Type de données

boolean

Alias
UMLS CUI [1]
C0086879
cardiac index < 2.4 l/min/m2
Description

Cardiac index

Type de données

boolean

Alias
UMLS CUI [1]
C0428776
there is evidence for abnormal renal function and/or diuretic resistance defined as: serum creatinine > 1.2 mg/dl or diuretic dosage of intravenous furosemide ≥
Description

Abnormal renal function Evidence of | Diuretic resistance | Creatinine measurement, serum | Furosemide Intravenous Daily Dose

Type de données

boolean

Alias
UMLS CUI [1,1]
C0151746
UMLS CUI [1,2]
C0332120
UMLS CUI [2,1]
C0012798
UMLS CUI [2,2]
C0013203
UMLS CUI [3]
C0201976
UMLS CUI [4,1]
C0016860
UMLS CUI [4,2]
C1522726
UMLS CUI [4,3]
C2348070
120 mg daily, or equivalent
Description

Furosemide Equivalent Intravenous Daily Dose

Type de données

boolean

Alias
UMLS CUI [1,1]
C0016860
UMLS CUI [1,2]
C0205163
UMLS CUI [1,3]
C1522726
UMLS CUI [1,4]
C2348070
4. lvef < 35%
Description

Left ventricular ejection fraction

Type de données

boolean

Alias
UMLS CUI [1]
C0428772
5. male or female 18-90 years of age
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
6. if female, no child-bearing potential or negative pregnancy test
Description

Gender | Childbearing Potential | Pregnancy test negative

Type de données

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C3831118
UMLS CUI [3]
C0427780
7. written informed consent
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
8. willingness to participate in required follow-up exams
Description

follow-up examination participation Willing

Type de données

boolean

Alias
UMLS CUI [1,1]
C0260832
UMLS CUI [1,2]
C0679823
UMLS CUI [1,3]
C0600109
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. acute q-wave myocardial infarction within past 7 days
Description

Q wave Related Myocardial Infarction

Type de données

boolean

Alias
UMLS CUI [1,1]
C0429090
UMLS CUI [1,2]
C0439849
UMLS CUI [1,3]
C0027051
2. post cardiotomy shock within past 30 days
Description

Cardiogenic Shock Post Cardiotomy

Type de données

boolean

Alias
UMLS CUI [1,1]
C0036980
UMLS CUI [1,2]
C0687676
UMLS CUI [1,3]
C0189758
3. cardiac surgery within past 14 days
Description

Cardiac Surgery

Type de données

boolean

Alias
UMLS CUI [1]
C0018821
4. bridge to transplant
Description

Bridge Related Transplant

Type de données

boolean

Alias
UMLS CUI [1,1]
C0456378
UMLS CUI [1,2]
C0439849
UMLS CUI [1,3]
C0040732
5. history of severe copd as defined as fev1 < 1.0 liter
Description

Severe chronic obstructive pulmonary disease | FEV1

Type de données

boolean

Alias
UMLS CUI [1]
C0730607
UMLS CUI [2]
C0748133
6. history of malignant arrhythmias defined as either:
Description

Cardiac Arrhythmia

Type de données

boolean

Alias
UMLS CUI [1]
C0003811
sustained ventricular tachycardia > 15 beats or more in length, not associated with a correctable cause, within the preceding 3 months, unless the patient presently has an implantable cardiac defibrillator.
Description

Sustained ventricular tachycardia | Implantable defibrillator

Type de données

boolean

Alias
UMLS CUI [1]
C0750197
UMLS CUI [2]
C0162589
history of ventricular fibrillation or sudden death, unless the patient presently has an implantable cardiac defibrillator
Description

Ventricular Fibrillation | Sudden death | Implantable defibrillator

Type de données

boolean

Alias
UMLS CUI [1]
C0042510
UMLS CUI [2]
C0011071
UMLS CUI [3]
C0162589
7. patients implanted with a resynchronization device within the previous 14 days or if there is a possibility of implant within 60 days following randomization
Description

Cardiac Resynchronization Therapy Defibrillator Implantation

Type de données

boolean

Alias
UMLS CUI [1,1]
C1322646
UMLS CUI [1,2]
C0021107
8. systolic pressure <80 mmhg
Description

Systolic Pressure

Type de données

boolean

Alias
UMLS CUI [1]
C0871470
9. requiring cardiopulmonary support type devices
Description

Cardiopulmonary resuscitator Patient need for

Type de données

boolean

Alias
UMLS CUI [1,1]
C0183001
UMLS CUI [1,2]
C0686904
10. platelets < 50,000/mm3 or other evidence of coagulopathy, inr greater than 1.5 in the absence of anticoagulation therapy.
Description

Platelet Count measurement | Blood Coagulation Disorder Evidence of | International Normalized Ratio | Anticoagulation Therapy Absence

Type de données

boolean

Alias
UMLS CUI [1]
C0032181
UMLS CUI [2,1]
C0005779
UMLS CUI [2,2]
C0332120
UMLS CUI [3]
C0525032
UMLS CUI [4,1]
C0003281
UMLS CUI [4,2]
C0332197
11. infection (wbc ≥ 12.5 x 103/ml, and or temperature ≥ 100.5°f/38°c)
Description

Communicable Diseases | White Blood Cell Count | Body temperature measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0009450
UMLS CUI [2]
C0023508
UMLS CUI [3]
C0886414
12. history of cerebral vascular accident (cva) or transient ischemic attacks (tia) within the last 3 months
Description

Cerebrovascular accident | Transient Ischemic Attack

Type de données

boolean

Alias
UMLS CUI [1]
C0038454
UMLS CUI [2]
C0007787
13. unwilling or unable to receive blood transfusion
Description

Blood Transfusion Unwilling

Type de données

boolean

Alias
UMLS CUI [1,1]
C0005841
UMLS CUI [1,2]
C0558080
14. inability to undergo treatment with heparin
Description

Heparin therapy Unable

Type de données

boolean

Alias
UMLS CUI [1,1]
C0522794
UMLS CUI [1,2]
C1299582
15. patients on dialysis or serum creatinine > 4.0 mg/dl
Description

Dialysis | Creatinine measurement, serum

Type de données

boolean

Alias
UMLS CUI [1]
C0011946
UMLS CUI [2]
C0201976
16. primary liver disease with bilirubin, sgot, or sgpt > 4x upper limit of normal
Description

Liver disease Primary | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement

Type de données

boolean

Alias
UMLS CUI [1,1]
C0023895
UMLS CUI [1,2]
C0205225
UMLS CUI [2]
C1278039
UMLS CUI [3]
C0201899
UMLS CUI [4]
C0201836
17. life expectancy from other disease < 12 months
Description

Life Expectancy Due to Disease

Type de données

boolean

Alias
UMLS CUI [1,1]
C0023671
UMLS CUI [1,2]
C0678226
UMLS CUI [1,3]
C0012634
18. patients who are active on the cardiac transplantation waiting list, unless there is a documented reason (large body habitus, highly sensitized, o blood group) to anticipate that transplant is unlikely within the subsequent 65 days.
Description

Patient on waiting list Heart Transplantation | Blood group O | Heart Transplantation Unlikely

Type de données

boolean

Alias
UMLS CUI [1,1]
C0422768
UMLS CUI [1,2]
C0018823
UMLS CUI [2]
C0427625
UMLS CUI [3,1]
C0018823
UMLS CUI [3,2]
C0750558
19. symptomatic patent foramen ovale or intracardiac shunt
Description

Patent Foramen Ovale Symptomatic | Shunt left-right intracardiac | Shunt right-left intracardiac

Type de données

boolean

Alias
UMLS CUI [1,1]
C0016522
UMLS CUI [1,2]
C0231220
UMLS CUI [2]
C0489643
UMLS CUI [3]
C0489644
20. patients diagnosed with clinically significant peripheral vascular disease, defined as absent pedal pulse or signs or symptoms of limb ischemia, including a history of intermittent claudication
Description

Peripheral Vascular Disease Clinical Significance | Pedal pulse Absent | Limb ischemia Signs and Symptoms | Intermittent Claudication

Type de données

boolean

Alias
UMLS CUI [1,1]
C0085096
UMLS CUI [1,2]
C2826293
UMLS CUI [2,1]
C0232157
UMLS CUI [2,2]
C0332197
UMLS CUI [3,1]
C2945695
UMLS CUI [3,2]
C0037088
UMLS CUI [4]
C0021775
21. patients with amyloidosis, thyroid induced heart failure, high output failure secondary to an arterio-venous fistula, and significant uncorrected primary valvular disease (with the exception of mitral regurgitation believed secondary to lv dilatation)
Description

Amyloidosis | Heart failure Due to Hyperthyroidism | High output heart failure Secondary to Arteriovenous fistula | Valvular disease Primary uncorrected Significant | Mitral Valve Insufficiency Secondary to Left ventricular dilatation

Type de données

boolean

Alias
UMLS CUI [1]
C0002726
UMLS CUI [2,1]
C0018801
UMLS CUI [2,2]
C0678226
UMLS CUI [2,3]
C0020550
UMLS CUI [3,1]
C0221045
UMLS CUI [3,2]
C0175668
UMLS CUI [3,3]
C0003855
UMLS CUI [4,1]
C3258293
UMLS CUI [4,2]
C0205225
UMLS CUI [4,3]
C4072785
UMLS CUI [4,4]
C0750502
UMLS CUI [5,1]
C0026266
UMLS CUI [5,2]
C0175668
UMLS CUI [5,3]
C0344911
Retour au début de la page

Similar models

Eligibility Heart Failure, Congestive NCT00357591

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Hospitalization Due to Decompensated cardiac failure | Inotropic agent Intravenous Patient need for | Vasodilator Agents Patient need for | Diuretic therapy Patient need for
Item
1. patients hospitalized due to decompensated heart failure who require iv inotropic and/or vasodilator and diuretic therapy
boolean
C0019993 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C0581377 (UMLS CUI [1,3])
C0304509 (UMLS CUI [2,1])
C1522726 (UMLS CUI [2,2])
C0686904 (UMLS CUI [2,3])
C0042402 (UMLS CUI [3,1])
C0686904 (UMLS CUI [3,2])
C0948575 (UMLS CUI [4,1])
C0686904 (UMLS CUI [4,2])
Therapeutic procedure Appropriate Heart failure | Angiotensin-Converting Enzyme Inhibitors | Adrenergic beta-Antagonists | intolerance to Angiotensin-Converting Enzyme Inhibitors | intolerance to Adrenergic beta-Antagonists | Medical contraindication Angiotensin-Converting Enzyme Inhibitors | Medical contraindication Adrenergic beta-Antagonists | Diuretics
Item
2. patients receiving appropriate medical therapy for heart failure, defined as ace inhibitors and beta blockers (all unless not tolerated or contraindicated) and diuretics, for 1 month prior to study entry
boolean
C0087111 (UMLS CUI [1,1])
C1548787 (UMLS CUI [1,2])
C0018801 (UMLS CUI [1,3])
C0003015 (UMLS CUI [2])
C0001645 (UMLS CUI [3])
C1744706 (UMLS CUI [4,1])
C0003015 (UMLS CUI [4,2])
C1744706 (UMLS CUI [5,1])
C0001645 (UMLS CUI [5,2])
C1301624 (UMLS CUI [6,1])
C0003015 (UMLS CUI [6,2])
C1301624 (UMLS CUI [7,1])
C0001645 (UMLS CUI [7,2])
C0012798 (UMLS CUI [8])
Dobutamine Dosage Minimum | Milrinone Dosage Minimum | Dopamine Dosage Minimum | Nesiritide Dosage Minimum | Nitroglycerin Dosage Minimum
Item
3. for at least 24 hours prior to inclusion into the study, the patient should be treated with a minimum dose of the following: dobutamine 2.5μg/kg/min or milrinone 0.3μg/kg/min or dopamine 5μg/kg/min. or nesiritide 0.01μg/kg/min or nitroglycerin 0.3
boolean
C0012963 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C1524031 (UMLS CUI [1,3])
C0128513 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C1524031 (UMLS CUI [2,3])
C0013030 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C1524031 (UMLS CUI [3,3])
C0054015 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C1524031 (UMLS CUI [4,3])
C0017887 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
C1524031 (UMLS CUI [5,3])
Nitroprusside Dosage Minimum | Combined Modality Therapy | Diuretic therapy | Pharmaceutical Preparations Dosage Stable
Item
µg/kg/min or nitroprusside 0.3 µg/kg/min or a combination of any of these agents, with diuretic therapy. doses of the above stated medications should be stable for 6 hours prior to inclusion into study. an increase in this dosage within the first 8 hours after enrollment is determined by the attending physician to be unlikely and the following definition of "not responding adequately to iv inotropic and/or vasodilator and diuretic therapy" is exhibited:
boolean
C0028193 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C1524031 (UMLS CUI [1,3])
C0009429 (UMLS CUI [2])
C0948575 (UMLS CUI [3])
C0013227 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0205360 (UMLS CUI [4,3])
Pulmonary Capillary Wedge Pressure
Item
pcwp is ≥ 20 mmhg at time of randomization and pcwp was ≥ 18 mmhg continuously for 24 hours or pcwp ≥ 20 mmhg continuously for 12 hours prior to randomization.
boolean
C0086879 (UMLS CUI [1])
Cardiac index
Item
cardiac index < 2.4 l/min/m2
boolean
C0428776 (UMLS CUI [1])
Abnormal renal function Evidence of | Diuretic resistance | Creatinine measurement, serum | Furosemide Intravenous Daily Dose
Item
there is evidence for abnormal renal function and/or diuretic resistance defined as: serum creatinine > 1.2 mg/dl or diuretic dosage of intravenous furosemide ≥
boolean
C0151746 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
C0012798 (UMLS CUI [2,1])
C0013203 (UMLS CUI [2,2])
C0201976 (UMLS CUI [3])
C0016860 (UMLS CUI [4,1])
C1522726 (UMLS CUI [4,2])
C2348070 (UMLS CUI [4,3])
Furosemide Equivalent Intravenous Daily Dose
Item
120 mg daily, or equivalent
boolean
C0016860 (UMLS CUI [1,1])
C0205163 (UMLS CUI [1,2])
C1522726 (UMLS CUI [1,3])
C2348070 (UMLS CUI [1,4])
Left ventricular ejection fraction
Item
4. lvef < 35%
boolean
C0428772 (UMLS CUI [1])
Age
Item
5. male or female 18-90 years of age
boolean
C0001779 (UMLS CUI [1])
Gender | Childbearing Potential | Pregnancy test negative
Item
6. if female, no child-bearing potential or negative pregnancy test
boolean
C0079399 (UMLS CUI [1])
C3831118 (UMLS CUI [2])
C0427780 (UMLS CUI [3])
Informed Consent
Item
7. written informed consent
boolean
C0021430 (UMLS CUI [1])
follow-up examination participation Willing
Item
8. willingness to participate in required follow-up exams
boolean
C0260832 (UMLS CUI [1,1])
C0679823 (UMLS CUI [1,2])
C0600109 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
Q wave Related Myocardial Infarction
Item
1. acute q-wave myocardial infarction within past 7 days
boolean
C0429090 (UMLS CUI [1,1])
C0439849 (UMLS CUI [1,2])
C0027051 (UMLS CUI [1,3])
Cardiogenic Shock Post Cardiotomy
Item
2. post cardiotomy shock within past 30 days
boolean
C0036980 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C0189758 (UMLS CUI [1,3])
Cardiac Surgery
Item
3. cardiac surgery within past 14 days
boolean
C0018821 (UMLS CUI [1])
Bridge Related Transplant
Item
4. bridge to transplant
boolean
C0456378 (UMLS CUI [1,1])
C0439849 (UMLS CUI [1,2])
C0040732 (UMLS CUI [1,3])
Severe chronic obstructive pulmonary disease | FEV1
Item
5. history of severe copd as defined as fev1 < 1.0 liter
boolean
C0730607 (UMLS CUI [1])
C0748133 (UMLS CUI [2])
Cardiac Arrhythmia
Item
6. history of malignant arrhythmias defined as either:
boolean
C0003811 (UMLS CUI [1])
Sustained ventricular tachycardia | Implantable defibrillator
Item
sustained ventricular tachycardia > 15 beats or more in length, not associated with a correctable cause, within the preceding 3 months, unless the patient presently has an implantable cardiac defibrillator.
boolean
C0750197 (UMLS CUI [1])
C0162589 (UMLS CUI [2])
Ventricular Fibrillation | Sudden death | Implantable defibrillator
Item
history of ventricular fibrillation or sudden death, unless the patient presently has an implantable cardiac defibrillator
boolean
C0042510 (UMLS CUI [1])
C0011071 (UMLS CUI [2])
C0162589 (UMLS CUI [3])
Cardiac Resynchronization Therapy Defibrillator Implantation
Item
7. patients implanted with a resynchronization device within the previous 14 days or if there is a possibility of implant within 60 days following randomization
boolean
C1322646 (UMLS CUI [1,1])
C0021107 (UMLS CUI [1,2])
Systolic Pressure
Item
8. systolic pressure <80 mmhg
boolean
C0871470 (UMLS CUI [1])
Cardiopulmonary resuscitator Patient need for
Item
9. requiring cardiopulmonary support type devices
boolean
C0183001 (UMLS CUI [1,1])
C0686904 (UMLS CUI [1,2])
Platelet Count measurement | Blood Coagulation Disorder Evidence of | International Normalized Ratio | Anticoagulation Therapy Absence
Item
10. platelets < 50,000/mm3 or other evidence of coagulopathy, inr greater than 1.5 in the absence of anticoagulation therapy.
boolean
C0032181 (UMLS CUI [1])
C0005779 (UMLS CUI [2,1])
C0332120 (UMLS CUI [2,2])
C0525032 (UMLS CUI [3])
C0003281 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
Communicable Diseases | White Blood Cell Count | Body temperature measurement
Item
11. infection (wbc ≥ 12.5 x 103/ml, and or temperature ≥ 100.5°f/38°c)
boolean
C0009450 (UMLS CUI [1])
C0023508 (UMLS CUI [2])
C0886414 (UMLS CUI [3])
Cerebrovascular accident | Transient Ischemic Attack
Item
12. history of cerebral vascular accident (cva) or transient ischemic attacks (tia) within the last 3 months
boolean
C0038454 (UMLS CUI [1])
C0007787 (UMLS CUI [2])
Blood Transfusion Unwilling
Item
13. unwilling or unable to receive blood transfusion
boolean
C0005841 (UMLS CUI [1,1])
C0558080 (UMLS CUI [1,2])
Heparin therapy Unable
Item
14. inability to undergo treatment with heparin
boolean
C0522794 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
Dialysis | Creatinine measurement, serum
Item
15. patients on dialysis or serum creatinine > 4.0 mg/dl
boolean
C0011946 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
Liver disease Primary | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
16. primary liver disease with bilirubin, sgot, or sgpt > 4x upper limit of normal
boolean
C0023895 (UMLS CUI [1,1])
C0205225 (UMLS CUI [1,2])
C1278039 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
Life Expectancy Due to Disease
Item
17. life expectancy from other disease < 12 months
boolean
C0023671 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C0012634 (UMLS CUI [1,3])
Patient on waiting list Heart Transplantation | Blood group O | Heart Transplantation Unlikely
Item
18. patients who are active on the cardiac transplantation waiting list, unless there is a documented reason (large body habitus, highly sensitized, o blood group) to anticipate that transplant is unlikely within the subsequent 65 days.
boolean
C0422768 (UMLS CUI [1,1])
C0018823 (UMLS CUI [1,2])
C0427625 (UMLS CUI [2])
C0018823 (UMLS CUI [3,1])
C0750558 (UMLS CUI [3,2])
Patent Foramen Ovale Symptomatic | Shunt left-right intracardiac | Shunt right-left intracardiac
Item
19. symptomatic patent foramen ovale or intracardiac shunt
boolean
C0016522 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0489643 (UMLS CUI [2])
C0489644 (UMLS CUI [3])
Peripheral Vascular Disease Clinical Significance | Pedal pulse Absent | Limb ischemia Signs and Symptoms | Intermittent Claudication
Item
20. patients diagnosed with clinically significant peripheral vascular disease, defined as absent pedal pulse or signs or symptoms of limb ischemia, including a history of intermittent claudication
boolean
C0085096 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
C0232157 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C2945695 (UMLS CUI [3,1])
C0037088 (UMLS CUI [3,2])
C0021775 (UMLS CUI [4])
Amyloidosis | Heart failure Due to Hyperthyroidism | High output heart failure Secondary to Arteriovenous fistula | Valvular disease Primary uncorrected Significant | Mitral Valve Insufficiency Secondary to Left ventricular dilatation
Item
21. patients with amyloidosis, thyroid induced heart failure, high output failure secondary to an arterio-venous fistula, and significant uncorrected primary valvular disease (with the exception of mitral regurgitation believed secondary to lv dilatation)
boolean
C0002726 (UMLS CUI [1])
C0018801 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C0020550 (UMLS CUI [2,3])
C0221045 (UMLS CUI [3,1])
C0175668 (UMLS CUI [3,2])
C0003855 (UMLS CUI [3,3])
C3258293 (UMLS CUI [4,1])
C0205225 (UMLS CUI [4,2])
C4072785 (UMLS CUI [4,3])
C0750502 (UMLS CUI [4,4])
C0026266 (UMLS CUI [5,1])
C0175668 (UMLS CUI [5,2])
C0344911 (UMLS CUI [5,3])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial